|
|
|
|
| LEADER |
03123nam a22005655i 4500 |
| 001 |
978-3-319-26821-7 |
| 003 |
DE-He213 |
| 005 |
20160315035647.0 |
| 007 |
cr nn 008mamaa |
| 008 |
160315s2016 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783319268217
|9 978-3-319-26821-7
|
| 024 |
7 |
|
|a 10.1007/978-3-319-26821-7
|2 doi
|
| 040 |
|
|
|d GrThAP
|
| 050 |
|
4 |
|a QR180-189.5
|
| 072 |
|
7 |
|a MJCM
|2 bicssc
|
| 072 |
|
7 |
|a MED044000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.079
|2 23
|
| 100 |
1 |
|
|a Escors, David.
|e author.
|
| 245 |
1 |
0 |
|a Myeloid-Derived Suppressor Cells and Cancer
|h [electronic resource] /
|c by David Escors, James E. Talmadge, Karine Breckpot, Jo A. Van Ginderachter, Grazyna Kochan.
|
| 250 |
|
|
|a 1st ed. 2016.
|
| 264 |
|
1 |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2016.
|
| 300 |
|
|
|a IX, 102 p. 8 illus. in color.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a SpringerBriefs in Immunology,
|x 2194-2773
|
| 505 |
0 |
|
|a Controversies in Neoplastic Myeloplasia -- Differentiation of Murine Myeloid-derived Suppressor Cells -- Human MDSCs -- Ex Vivo MDSC Differentiation Models -- Immunoregulatory myeloid cells in the tumor microenvironment -- Signal Transducer and Activation of Transcription 3: A Master Regulator of Myeloid-derived Suppressor Cells -- Future Perspectives.
|
| 520 |
|
|
|a The book starts with an introduction to and history of myeloid-derived suppressor cells (MDSCs), followed by a description of their differentiation, their role in the tumour microenvironment and their therapeutic targeting. It closes with an outlook on future developments. In cancer patients, myelopoiesis is perturbed and instead of generating immunogenic myeloid cells (such as dendritic cells, inflammatory macrophages and granulocytes), there is an increase in highly immature MDSCs. These cells are distributed systemically, resulting in general immunosuppression. They also infiltrate tumours, promoting their progression and metastasis by inhibiting the natural anti-tumour immune response. As these cells also interact with classical anti-neoplastic treatments, they have become major therapeutic targets in the pharmaceutical industry and in oncology research.
|
| 650 |
|
0 |
|a Medicine.
|
| 650 |
|
0 |
|a Cancer research.
|
| 650 |
|
0 |
|a Immunology.
|
| 650 |
|
0 |
|a Oncology.
|
| 650 |
|
0 |
|a Cell biology.
|
| 650 |
1 |
4 |
|a Biomedicine.
|
| 650 |
2 |
4 |
|a Immunology.
|
| 650 |
2 |
4 |
|a Cancer Research.
|
| 650 |
2 |
4 |
|a Oncology.
|
| 650 |
2 |
4 |
|a Cell Biology.
|
| 700 |
1 |
|
|a Talmadge, James E.
|e author.
|
| 700 |
1 |
|
|a Breckpot, Karine.
|e author.
|
| 700 |
1 |
|
|a Van Ginderachter, Jo A.
|e author.
|
| 700 |
1 |
|
|a Kochan, Grazyna.
|e author.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783319268194
|
| 830 |
|
0 |
|a SpringerBriefs in Immunology,
|x 2194-2773
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1007/978-3-319-26821-7
|z Full Text via HEAL-Link
|
| 912 |
|
|
|a ZDB-2-SBL
|
| 950 |
|
|
|a Biomedical and Life Sciences (Springer-11642)
|
